Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community
Source: pixabay.com

Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community

The U.S. FDA just announced that it has accepted Genentech’s supplemental New Drug Application (sNDA) and has granted Priority Review for Zelboraf (vemurafenib) in patients with Erdheim-Chester disease from the…

Continue Reading Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community
This Study Could Yield Urgently-Needed Data for the Prader-Willi Syndrome Community
Source: pixabay.com

This Study Could Yield Urgently-Needed Data for the Prader-Willi Syndrome Community

Soleno Therapeutics, Inc. of Capnia reported in early July of this year that the company plans to start a Phase 3 clinical trial for evaluating diazoxide choline controlled-release (DCCR) in…

Continue Reading This Study Could Yield Urgently-Needed Data for the Prader-Willi Syndrome Community
Correcting Disease-Causing Genes in Humans: One Small Step for Humans, One Giant Leap for Humankind
Source: pixabay.com

Correcting Disease-Causing Genes in Humans: One Small Step for Humans, One Giant Leap for Humankind

Genetic engineering has, for a long time, been a highly heated and contested issue. One must weigh the ethical ramifications and risks of engineering human embryos with the huge potential…

Continue Reading Correcting Disease-Causing Genes in Humans: One Small Step for Humans, One Giant Leap for Humankind
Sarcoidosis Patients Face a Higher Risk of Developing This Condition
Source: https://pixabay.com/en/boy-man-sitting-thinking-waiting-1149957/

Sarcoidosis Patients Face a Higher Risk of Developing This Condition

A report titled, “Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013,” recently released information that patients with sarcoidosis have a 3-fold increased risk for…

Continue Reading Sarcoidosis Patients Face a Higher Risk of Developing This Condition